How does an organism know when it must produce a protein and in what amount? Clever control mechanisms are responsible for the regulation of protein biosynthesis. One such type of mechanism, discovered only a few years ago, is riboswitches, which function as a sort of "off" switch for the production of certain proteins.
These could be a useful point of attack for novel antibiotics if it were possible to find drugs that bind to the switches of pathogens and "turn off" the biosynthesis of essential proteins in bacteria or fungi. A team at the interdisciplinary Life and Medical Sciences Center at the University of Bonn has now taken a meaningful step toward a better understanding of riboswitches. Researchers led by Michael Famulok have successfully produced hairpin-shaped RNA molecules that are able to differentiate between riboswitches in the on and off states.
In order to produce a specific protein, a cell first generates a copy of the corresponding gene of the DNA. This blueprint containing the construction plans for the protein is called messenger RNA (mRNA). By using its ribosomes, the cell then reads the mRNA code and synthesizes the protein. Some proteins can activate a "switch" to halt their own synthesis once they are present in sufficient quantity. This is because the mRNA does not only contain the genetic code for the protein but can also contain segments with a switching function. The protein or a closely connected metabolite binds to this riboswitch and changes its spatial structure such that the mRNA segments controlling the protein production can no longer be read off. For example, when the metabolite thiamine pyrophosphate (TPP) binds to the thiM riboswitch of E. coli bacteria, an mRNA segment recognized by the ribosome as the starting point for "reading" the plan is covered up.
Michael Famulok and his team searched for a probe that can differentiate between off and on. Aptamers are known for their ability to differentiate between different states of proteins. Aptamers are short RNA strands that adopt a specific spatial structure and, like antibodies, selectively bind to specific target molecules. So, why not riboswitches" Over several steps starting from a "library", a randomly generated large number of highly varied RNA sequences, the scientists selected two short hairpin-shaped aptamers that bind very strongly and specifically to the riboswitch in the "on" position. It turned out that the two hairpins bind to different locations: one to the TPP binding site and the other to a domain responsible for the change in structure of the riboswitch. Both hairpins are crowded when TPP molecules move the riboswitch to the "off" conformation.
Famulok and his team hope to use these aptamers to gain new insights into the function of riboswitches. This could help in the search for a completely new class of antimicrobial agents that block the bacterial thiM riboswitch just like TPP.
Citation: Michael Famulok, RNA Ligands That Distinguish Metabolite-Induced Conformations in the TPP Riboswitch, Angewandte Chemie International Edition, doi: 10.1002/anie.200603166
Source: John Wiley & Sons
Related stories:
Hairpins for Switches: Artificial RNA ligands differentiate between on and off states of riboswitches
How does an organism know when it must produce a protein and in what amount? Clever control mechanisms are responsible for the regulation of protein biosynthesis. One such type of mechanism, discovered only a few years ago, is riboswitches, which function as a sort of “off” switch for the production of certain proteins. These could be a useful point of attack for novel antibiotics if it were possible to find drugs that bind to the switches of pathogens and “turn off” the biosynthesis of essential proteins in bacteria or fungi.
Researchers Discover Remnant of an Ancient 'RNA World'
(PhysOrg.com) -- Some bacterial cells can swim, morph into new forms and even become dangerously virulent - all without initial involvement of DNA. Yale University researchers describe Friday in the journal
Science how bacteria accomplish this amazing feat - and in doing so provide a glimpse of what the earliest forms of life on Earth may have looked like.
As rates rise, researchers find better way to identify melanoma
University of Rochester Medical Center researchers found a new protein produced excessively in malignant melanoma, a discovery that is particularly relevant as skin cancer rates climb dramatically among young women.
Location, location, location
Neuroscientists at Georgetown University Medical Center have solved a mystery that lies at the heart of human learning, and they say the solution may help explain some forms of mental retardation as well as provide clues to overall brain functioning.
Combining medical knowledge to save lives
European researchers hope to gain more insight into cardiovascular disease by combining clinical, laboratory and metabolic records with genomic data.
Cardiovascular disease (CVD) is the biggest killer among chronic diseases, claiming 17 million lives globally every year. Yet doctors can only attribute 50% of cardiovascular diseases to known risk factors.
Researchers show antibody to breast cancer-secreted protein blocks metastasis
Scientists at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have made a key discovery about the mechanism of breast cancer metastasis, the process by which cancer spreads. Focusing on a gene dubbed "Dachshund," or DACH1, they are beginning to pinpoint new therapeutic targets to halt the spread of cancer.
UF scientists to work with German firm in prostate cancer treatment research
University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.
Gene variation may be why some don't respond to cholesterol-lowering drugs
A variation in the way the body processes a single protein may explain why some people don't respond well to drugs that lower "bad" cholesterol, according to a report in
Circulation: Journal of the American Heart Association.